Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Inotek takes in $18mm through sale of preferred shares; closes financing at $23.6mm

Executive Summary

Inotek Pharmaceuticals Corp. (ophthalmic therapeutics) has raised $18mm through the sale of Series D preferred shares. New backer Devon Park Bioventures led and was joined by current shareholders Rho Ventures, Care Capital, Pitango Venture Capital, MedImmune Ventures, and Bio*One Capital. Funds will be used to bring INO8875 through Phase II for glaucoma.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies